Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Frontiers in Medicine|June 16, 2023
Interdisciplinary management of mpox-related local complications: report on a series of casesMaría Gamo Guerrero, Ana Simón Gozalbo, Mariángeles Martín Díaz, et al.
Journal of Medical Virology|April 10, 2020
Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detectionAna Avellon, Aftab Ala, Antonio Diaz, et al.
Frontiers in Medicine|September 27, 2021
Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019Felipe Pérez-García, Rebeca Bailén, Juan Torres-Macho, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 25, 2022
Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin DMontserrat Torres, Guiomar Casado, Lorena Vigón, et al.
Microorganisms|July 27, 2024
DNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19César Fernández-de-Las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, et al.
Journal of Clinical Medicine|May 14, 2025
Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 PainCésar Fernández-de-Las-Peñas, Anabel Franco-Moreno, María Ruiz-Ruigómez, et al.
Biomedicines|August 29, 2024
Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the <i>ACE2</i> Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 InfectionCésar Fernández-de-Las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, et al.
BMC Public Health|November 15, 2024
Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate studyFernando Chacón, Luis Morano, Jordi Navarro, et al.
Open Forum Infectious Diseases|December 18, 2020
Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016Ignacio Perez Valero, Alfonso Cabello, Pablo Ryan, et al.
Journal of Translational Medicine|December 30, 2025
IFNL4-rs12979860 CC genotype predisposes to accelerated terminal exhaustion and senescence in HIV/HCV-chronic infectionSonia Arca-Lafuente, Violeta Lara-Aguilar, Manuel Llamas-Adán, et al.
Pageof 14